(Q38731776)

5 September 2017

title

K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? (English)

1 reference

5 September 2017

1 reference

1

Ruth Nussinov

1 reference

5 September 2017

3

Chung-Jung Tsai

1 reference

5 September 2017

4

Hyunbum Jang

1 reference

5 September 2017

6

Ozlem Keskin

1 reference

5 September 2017

2

Serena Muratcioglu

1 reference

5 September 2017

5

Attila Gursoy

1 reference

5 September 2017

language of work or name

English

0 references

publication date

12 February 2016

1 reference

Expert Opinion on Therapeutic Targets

5 September 2017

published in

1 reference

5 September 2017

volume

20

1 reference

5 September 2017

issue

7

1 reference

5 September 2017

page(s)

831-842

1 reference

Novel targets in pancreatic cancer research

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Molecular landscape of pancreatic cancer: implications for current clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Drugging the undruggable RAS: Mission possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

TRAPP: a tool for analysis of transient binding pockets in proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Compound activity prediction using models of binding pockets or ligand properties in 3D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

'Pathway drug cocktail': targeting Ras signaling based on structural pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Flexibility and small pockets at protein-protein interfaces: New insights into druggability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Protein-protein interactions as druggable targets: recent technological advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Unraveling structural mechanisms of allosteric drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Allostery and population shift in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The different ways through which specificity works in orthosteric and allosteric drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Allostery in disease and in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The design of covalent allosteric drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Evading inhibitory constraints--destabilizing p110α/p85α interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Synthesis and function of 3-phosphorylated inositol lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Structural basis for activation and inhibition of class I phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Calmodulin activates phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A frequent kinase domain mutation that changes the interaction between PI3K and the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Dynamic allostery: linkers are not merely flexible

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Ras signalling and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Developmentally-regulated expression of murine K-ras isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

K-ras is an essential gene in the mouse with partial functional overlap with N-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Polylysine domain of K-ras 4B protein is crucial for malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A New View of Ras Isoforms in Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

RAS Interaction with PI3K: More Than Just Another Effector Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

RAS oncogenes: weaving a tumorigenic web

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Functional specificity of ras isoforms: so similar but so different

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A comprehensive survey of Ras mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

KRAS: feeding pancreatic cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Identification of differently expressed genes in human colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A study on the levels of calmodulin and DNA in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Ca2+/calmodulin-dependent protein kinase IIγ enhances stem-like traits and tumorigenicity of lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A broad view of scaffolding suggests that scaffolding proteins can actively control regulation and signaling of multienzyme complexes through allostery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Oncogenic KRAS signalling in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

The pancreas cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

'Latent drivers' expand the cancer mutational landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Molecular pathogenesis of pancreatic cancer and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Molecular genetics of pancreatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Metastatic pancreatic cancer is dependent on oncogenic Kras in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Targeting protein prenylation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Brief overview of selected approaches in targeting pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Smarter drugs emerging in pancreatic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A review on anticancer potential of bioactive heterocycle quinoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

PQ1, a quinoline derivative, induces apoptosis in T47D breast cancer cells through activation of caspase-8 and caspase-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

An indolylquinoline derivative promotes apoptosis in human lung cancer cells by impairing mitochondrial functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Metabolic Dependencies in RAS-Driven Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Inhibitors of Ras-SOS Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

GTP-Dependent K-Ras Dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

High-Affinity Interaction of the K-Ras4B Hypervariable Region with the Ras Active Site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Regulation of RAF protein kinases in ERK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

GTP Binding and Oncogenic Mutations May Attenuate Hypervariable Region (HVR)-Catalytic Domain Interactions in Small GTPase K-Ras4B, Exposing the Effector Binding Site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Stabilization of Protein-Protein Interactions in chemical biology and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Helix mimetics: Recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Using a Fragment-Based Approach To Target Protein-Protein Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

Structural biology and drug discovery for protein-protein interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

YAP regulates S-phase entry in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2016.1135131

10.1517/14728222.2016.1135131

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference